Business Context and Reporting Period
Company: Amphastar Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 30, 2016
Event: Entry into and termination of a material definitive agreement regarding the distribution of the Company's enoxaparin product.
Key Financial Metrics
This filing does not contain specific financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The document focuses exclusively on the legal terms of a distribution agreement amendment.
Material Changes
- Agreement Amendment: On June 30, 2016, Amphastar and Actavis Laboratories FL, Inc. (formerly Watson Laboratories/Andrx) entered into a Seventh Amendment and Termination Agreement regarding their 2005 Distribution Agreement for enoxaparin.
- Non-Competition Removal: The Amendment deletes Section 2.2.3 of the original agreement, which contained non-competition provisions, effective immediately.
- Termination Timeline: The Agreement will terminate on the earlier of January 1, 2017, or 30 days after Actavis notifies Amphastar that it has less than 30 days of inventory remaining.
- Inventory Obligations: Actavis must use "Commercially Reasonable Efforts" to sell remaining inventory. If Amphastar or a new distributor sells the product in the retail market prior to the Termination Date, Actavis may terminate the agreement and require Amphastar to repurchase all remaining inventory at the price Actavis paid.
- Future Distribution: Amphastar retains the right to appoint a new distributor effective immediately, subject to the restriction on selling in the retail market prior to the Termination Date.
Outlook, Risks, and Management Commentary
- Future Sales Strategy: Upon termination, Amphastar intends to continue selling enoxaparin to the U.S. retail market through new distributors, independent sales representatives, or direct sales efforts.
- Success Risk: Management explicitly states that no assurance can be given that efforts to sell the enoxaparin product to the retail market will be successful.
- Regulatory Disclosure: The information regarding future sales efforts is furnished under Regulation FD and is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the exact date Actavis provides notice of low inventory to determine the actual Termination Date.
- Monitor the appointment of any new distributors for the enoxaparin product.
- Review future quarterly reports for revenue impact related to the transition from Actavis to new distribution channels.
- Assess the risk of inventory repurchase costs if the Company accelerates sales prior to the agreed Termination Date.